ETON Eton Pharmaceuticals Inc
Price (delayed)
$13.26
Market cap
$355.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.15
Enterprise value
$370.58M
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI®
Highlights
ETON's equity has surged by 58% year-on-year and by 53% since the previous quarter
ETON's EPS is up by 32% since the previous quarter
The quick ratio has contracted by 33% YoY and by 22% from the previous quarter
The gross margin has contracted by 11% YoY
Key stats
What are the main financial stats of ETON
Market
Valuations
Earnings
Shares outstanding
26.82M
Market cap
$355.6M
Enterprise value
$370.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
14.02
Price to sales (P/S)
8.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.43
Revenue
$39.28M
Gross profit
$23.68M
Operating income
-$2.33M
Net income
-$3.82M
EBIT
-$2.6M
EBITDA
-$1.38M
Free cash flow
$943,000
Per share
Balance sheet
Liquidity
EPS
-$0.15
EPS diluted
-$0.15
Free cash flow per share
$0.04
Book value per share
$0.95
Revenue per share
$1.52
TBVPS
$1.59
Total assets
$76.12M
Total liabilities
$51.7M
Debt
$29.92M
Equity
$24.43M
Working capital
$21.07M
Debt to equity
1.22
Current ratio
2.06
Quick ratio
1.02
Net debt/EBITDA
-10.85
Margins
Efficiency
Dividend
EBITDA margin
-3.5%
Gross margin
60.3%
Net margin
-9.7%
Operating margin
-5.9%
Return on assets
-8.8%
Return on equity
-22%
Return on invested capital
-46%
Return on capital employed
-4.6%
Return on sales
-6.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ETON stock price
How has the Eton Pharmaceuticals stock price performed over time
Intraday
3.92%
1 week
-0.9%
1 month
-15.54%
1 year
260.33%
YTD
-0.45%
QTD
2.16%
Financial performance
How have Eton Pharmaceuticals's revenue and profit performed over time
Revenue
$39.28M
Gross profit
$23.68M
Operating income
-$2.33M
Net income
-$3.82M
Gross margin
60.3%
Net margin
-9.7%
The company's operating margin rose by 46% QoQ
The operating income has grown by 41% from the previous quarter
The net margin has grown by 36% since the previous quarter
The company's net income rose by 30% QoQ
Growth
What is Eton Pharmaceuticals's growth rate over time
Valuation
What is Eton Pharmaceuticals stock price valuation
P/E
N/A
P/B
14.02
P/S
8.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.43
ETON's EPS is up by 32% since the previous quarter
ETON's equity has surged by 58% year-on-year and by 53% since the previous quarter
The stock's price to book (P/B) is 48% more than its last 4 quarters average of 9.1 but 2.9% less than its 5-year quarterly average of 13.9
ETON's P/S is 97% below its 5-year quarterly average of 266.4 but 83% above its last 4 quarters average of 4.6
The revenue is up by 20% YoY and by 9% QoQ
Efficiency
How efficient is Eton Pharmaceuticals business performance
The return on assets has dropped by 175% year-on-year but it has grown by 48% since the previous quarter
Eton Pharmaceuticals's ROIC has soared by 94% YoY
ETON's return on sales has dropped by 78% year-on-year but it has surged by 60% since the previous quarter
Eton Pharmaceuticals's ROE has increased by 39% from the previous quarter
Dividends
What is ETON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ETON.
Financial health
How did Eton Pharmaceuticals financials performed over time
ETON's total assets is 47% more than its total liabilities
The company's total liabilities has surged by 160% QoQ
ETON's total assets has soared by 140% YoY and by 112% from the previous quarter
The debt is 22% greater than the equity
ETON's equity has surged by 58% year-on-year and by 53% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.